UNSPSC 51422412: Flumedroxone

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H29F3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K80185F39X, chemically known as 17-hydroxy-6alpha-(trifluoromethyl)pregn-4-ene-3,20-dione but generally known as flumedroxone, which bears US NIH Compound Identifier 71881. European Medicines Agency schedules Flumedroxone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07695MIG.

UNSPSC 51422412 Flumedroxone, a Commodity code, describes pharmaceutical products that state and local governments procure for public health and emergency response initiatives. Recent solicitation activity shows state and local agencies buying naloxone and drug deactivation systems for community health programs and exploring direct-to-manufacturer prescription delivery models. Seminole County, Florida and the Texas Health and Human Services Commission represent the kinds of issuing bodies active under this code — county health departments and state health agencies pursuing competitive procurements to support opioid response, harm reduction, and pharmacy benefit programs. Work solicited ranges from straightforward annual purchases of ready-made pharmaceutical products with quarterly delivery cycles to exploratory Request for Information (RFI) phases that establish vendor capabilities for future direct-contracting arrangements outside traditional pharmacy benefit manager and group purchasing organization channels.

Recent activity concentrates in Florida and Texas. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to solicit vendor information on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with a response deadline of April 3, 2026. Both procurements require vendors to meet standard compliance obligations including E-Verify certification, drug-free workplace requirements, and appropriate insurance coverage; the Seminole County contract offers an initial two-year term with a one-year renewal option and includes a three-month probationary termination period.